324548-45-0 Usage
Description
(S)-Bupropion Hydrochloride, also known as hydrochloride salt of (S)-Bupropion, is a chiral compound belonging to the aminoketone class of antidepressants. It functions as a selective inhibitor of dopamine uptake, playing a crucial role in the modulation of neurotransmitter levels in the brain. This property makes it a valuable pharmaceutical agent for various therapeutic applications.
Uses
Used in Pharmaceutical Industry:
(S)-Bupropion Hydrochloride is used as an antidepressant medication for the treatment of major depressive disorder. It helps alleviate symptoms of depression by selectively inhibiting the reuptake of dopamine, thereby increasing its availability in the synaptic cleft and promoting a balanced mood.
Additionally, (S)-Bupropion Hydrochloride is used as an aid in smoking cessation. Its mechanism of action involves reducing the pleasurable effects of nicotine, which helps to decrease the cravings and withdrawal symptoms associated with quitting smoking. This makes it a valuable tool in supporting individuals in their efforts to stop smoking and improve their overall health.
Check Digit Verification of cas no
The CAS Registry Mumber 324548-45-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,2,4,5,4 and 8 respectively; the second part has 2 digits, 4 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 324548-45:
(8*3)+(7*2)+(6*4)+(5*5)+(4*4)+(3*8)+(2*4)+(1*5)=140
140 % 10 = 0
So 324548-45-0 is a valid CAS Registry Number.
324548-45-0Relevant articles and documents
COMPOSITIONS AND METHODS FOR TREATING DEPRESSION, ADHD AND OTHER CENTRAL NERVOUS SYSTEM DISORDERS EMPLOYING NOVEL BUPROPION COMPOUNDS, AND METHODS FOR PRODUCTION AND USE OF NOVEL BUPROPION COMPOUNDS AND FORMULATIONS
-
Page/Page column 36-37, (2012/09/21)
Compositions and methods are disclosed using a purified (R)(-) enantiomer of bupropion to treat central nervous system disorders with fewer side effects compared to those seen in subjects treated with racemic bupropion. Additionally disclosed are methods and intermediates for producing enantiomerically purified (R)(-) bupropion, stable pharmaceutical formulations of (R)(-) bupropion, and pharmaceutical products and kits comprising (R)(-) bupropion for clinical use.
